1026087-26-2

Upstream product

• 1026087-18-2 3-{[(3,5-bis-trifluoromethyl-benzyl)-(2-methyl-2H-tetrazol-5-yl)-amino]-methyl}-5-trifluoromethyl-pyridine-2-carboxylic acid methoxyl-methyl-amide 
• 925-90-6 ethylmagnesium bromide 

Downstream Products

• 1026087-35-3 (Z)-1-(3-{[(3,5-bis-trifluoromethyl-benzyl)-(2-methyl-2H-tetrazol-5-yl)-amino]-methyl}-5-trifluoromethyl-pyridine-2-yl)-propan-1-one O-methyl-oxime 
• 1026087-32-0 (E)-1-(3-{[(3,5-bis-trifluoromethyl-benzyl)-(2-methyl-2H-tetrazol-5-yl)-amino]-methyl}-5-trifluoromethyl-pyridine-2-yl)-propan-1-one O-methyl-oxime 
• 1026137-01-8 1-(3-{[(3,5-bis-trifluoromethyl-benzyl)-(2-methyl-2H-tetrazol-5-yl)-amino]-methyl}-5-trifluoromethyl-pyridine-2-yl)-propan-1-ol 

Relevant academic research and scientific papers

ORGANIC COMPOUNDS

The present invention provides a compound of formula (I), said compound is an inhibitor of CETP, and thus can be employed for the treatment of a disorder or disease mediated by CETP or responsive to the inhibition of CETP.

HETEROCYCLIC DERIVATIVES AS CETP INHIBITORS

The present invention provides a compound of formula (I), said compound is an inhibitor of CETP, and thus can be employed for the treatment of a disorder or disease mediated by CETP or responsive to the inhibition of CETP.